Recent Tech Transfer Deals, April 2012
This article was originally published in Start Up
START-UP ’s monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.
You may also be interested in...
Biogen and Denali entered into a potential $2.15bn alliance for Denali’s DNL151 for Parkinson’s disease and other neurodegenerative diseases. Siemens Healthineers announced plans to acquire Varian Medical for $16.4bn. Financing reached $7.9bn in biopharma, $501m in device, and $639m in diagnostics.
Daiichi Sankyo partnered its Phase I DS-1062 for non-small cell lung cancer and triple negative breast cancer with AstraZeneca in a deal that could be worth up to $6bn. Medtronic entered into an agreement to acquire Medicrea in an all-cash tender offer for total consideration of approximately $228m (including approximately $57M of net cash and liabilities). Financing reached $11.7bn in biopharma, $1.4bn in device, and $597m in diagnostics.
During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.